
|Videos|October 11, 2016
Promising Alzheimer Antibody-Based Immunotherapy
Author(s)Bobby Lazzara, MD
Dr. Bobby Lazzara reports on a clinical trial of aducanumab, a human monoclonal antibody, in patients with prodromal or mild Alzheimer disease.
Advertisement
Aducanumab, a human monoclonal antibody, selectively targets aggregated amyloid-β. In this Medical News Minute, developed exclusively for Neurology Times, Dr. Bobby Lazzara discusses a
Advertisement
Latest CME
Advertisement
Advertisement
Trending on NeurologyLive - Clinical Neurology News and Neurology Expert Insights
1
uniQure Submits BLA for Gene Therapy in HD, AAN, AHS Issue Updated Guideline on Migraine Prevention, CTE Prevalence, Brain Donation Findings in Former NFL Players
2
EU Approves Modified-Release Carbidopa/Levodopa Capsules for Parkinson Disease Motor Fluctuations
3
Phase 4 Study Highlights Valbenazine's Positive Impact on Patient-Reported Quality of Life, Daily Functioning in Tardive Dyskinesia
4
Ultragenyx' Apazunersen Fails Primary End Point in Phase 3 Angelman Trial
5














